New trends in the treatment of bone metastasis.
Bone metastasis is often the penultimate harbinger of death for many cancer patients. Bone metastases are often associated with fractures and severe pain resulting in decreased quality of life. Accordingly, effective therapies to inhibit the development or progression of bone metastases will have important clinical benefits. To achieve this goal understanding the mechanisms through which bone metastases develop and progress may provide targets to inhibit the metastases. In the past few years, there have been advances in both understanding the mechanisms through which bone metastases develop and how they impact bone remodeling. Additionally, gains in promising clinical strategies to target bone metastases have been developed. In this prospectus, we will discuss some of these advances.
Keller
Evan T
ET
Department of Urology, University of Michigan, Ann Arbor, Michigan 48109, USA. etkeller@umich.edu
Dai
Jinlu
J
Escara-Wilke
June
J
Hall
Christopher L
CL
Ignatoski
Kathleen
K
Taichman
Russell S
RS
Keller
Jill
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D010014:Osteolysis / Q000628:therapy; D053244:Osteoprotegerin / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy; D053245:RANK Ligand / Q000378:metabolism
D000970:Antineoplastic Agents; D004164:Diphosphonates; D053244:Osteoprotegerin; D053245:RANK Ligand